Jaguar's MVID Trial Extension Progress Won't Resolve Looming Liquidity Crisis

What happened

Jaguar Health announced that all randomized pediatric MVID patients in its pivotal crofelemer trial have entered the single-blind extension phase, supporting its plan to file an NDA in mid-2027. This clinical milestone does not alter the company's acute financial distress: as of Q3 2025, Jaguar had only $3.5M cash against $36.1M current liabilities and faces a steep royalty step-up to $27M annually starting April 2026. The trial's progress may improve the odds of future regulatory success, but the company still needs substantial external funding or a major partnership to survive until an NDA. Investors should view this announcement as incremental positive clinical news rather than a de-risking event, as the core problem remains the unsustainable capital structure and ongoing dilution. Management's ability to fund the extension phase without further equity issuance is unproven, and the market likely will not re-rate the stock meaningfully on this news alone.

Implication

For investors, the completion of the crossover trial and entry into the extension phase indicates that crofelemer for MVID remains on track, but it does not address the company's going-concern status or the $27M annual royalty minimums that begin in April 2026. The stock remains a high-risk, binary outcome play where a positive NDA filing in 2027 is too far away to offset near-term insolvency risk. A material rerating would require evidence of a binding royalty/debt restructuring or a large upfront partnership covering 2026 obligations, neither of which has been announced. Until such a transaction appears, each clinical update should be treated as a possible financing narrative tool rather than a fundamental value driver. Existing shareholders should consider the opportunity to trim into strength, while new investors should wait for clear signs of balance sheet repair before considering a speculative position.

Thesis delta

The master thesis remains a STRONG SELL with expected value around $1.00 per share, as the news does not alter the structural financial challenges. However, the continued advancement of the MVID program slightly increases the probability of the bull case (currently 10%), where a future partnership or approval could unlock value. This is offset by unchanged high bear case probability (55%) driven by liquidity and royalty obligations. Overall, no change to the rating or near-term outlook.